Reaction Biology Europe has provided their services for several projects with us, including establishing an orthotopic tumor model and PK/PD studies. I was very impressed, not only by their level of expertise and professionalism but also by their enthusiasm and drive to deliver. The insightful advice they provide has been instrumental to our successes and their collegial and “can do” attitude make them a pleasure to team up with!
You are our No 1 CRO for cancer studies and while we know that we are sometimes a bit difficult (many protocol changes on short notice) we appreciate even more your flexibility and your motivation and attitude to deliver correct results. We look forward to many more studies with you to come.
I have worked with Reaction Biology Europe and Reaction Biology Corp. for more than 5 years on several interesting projects. These have ranged from routine enzyme screening to more complex kinome-scan and in-cell target engagement work. The results of these endeavors have led to a series of top-tier publications. This coupled with exceptional customer service means I have no hesitation to recommend Reaction Biology Corp. and Reaction Biology Europe as research partners.
Reaction Biology Europe has provided their service for numerous projects with us, especially on multiple kinase assays (under the name ProQinase) which have guided our way through drug development. I was very impressed not only by their level of expertise and professionalism but also by their enthusiasm and drive to deliver without delay. The insightful advice they provide has been instrumental to our successes, and the reproducibility, quality, and reporting of the results have been outstanding throughout the many years we have been working together.
We have worked with Reaction Biology Europe for 3 years on in vivo drug development assays. They have provided their services from routine PK through efficacy and custom BLI studies in tumor models, consistently generating high-quality results that guided our development process. Their expertise, responsiveness, and professionalism make Reaction Biology stand out from among the usual CROs, and we are happy to recommend them as research partners.
The Protein Kinases and Phosphorylation Conference
Visit us in-person @ PKPSRC22
Tumor Immunology Meets Oncology (TIMO) XVI
Meet us at TIMO 2022 in Germany
Tumor Models for Combination Targeted Oncology
Meet us at the 10th annual Tumor Models Conference in Boston
Reaction Biology Announces Expansion of Executive Leadership Team with Key Appointments in Commercial and Human Resources Functions
Reaction Biology today announced the expansion of its Executive Leadership team with the appointments of Alan Findlater to the position of Chief Commercial Officer (CCO) and Emily Doyle to the position of Chief People Officer (CPO). Mr. Findlater and Ms. Doyle will also serve as members of the Executive Committee, effective immediately. These new appointments strengthen Reaction’s commercial and human resources functional areas.
New Data at AACR Showcase Reaction Biology’s Innovative Approach to Oncology Drug Discovery Services
New diacylglycerol kinase assay panel provides researchers for the first time with ten new lipid
kinase targets
New systems biology approach enhances preclinical characterization of the WEE-1 inhibitor
adavosertib
Reaction Biology Announces Appointment of Richard S. Kollender to Chief Financial Officer and Chief Business Officer
Reaction Biology today announced the appointment of Richard S. Kollender to the positions of Chief Financial Officer (CFO), Chief Business Officer (CBO) and member of the Executive Committee, effective immediately, to further strengthen the leadership team and support the Company’s next stage of growth.
.gif)